Gossamer Bio (GOSS) Cash & Current Investments (2018 - 2026)

Gossamer Bio's Cash & Current Investments history runs 9 years deep, the most recent figure standing at $99.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 61.53% year-over-year to $99.2 million; the TTM figure through Mar 2026 stood at $99.2 million (down 61.53% YoY), while the FY2025 annual figure was $136.9 million, down 49.98% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $99.2 million, down from $136.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $354.5 million in Q2 2024, with the low at $39.9 million in Q3 2022.
• The 5-year median for Cash & Current Investments is $222.2 million (2022), against an average of $213.9 million.
• Peak annual rise in Cash & Current Investments reached 2440.52% in 2022, while the deepest fall reached 81.31% in 2022.
• Gossamer Bio's Cash & Current Investments stood at $255.7 million in 2022, then rose by 15.94% to $296.4 million in 2023, then slipped by 7.65% to $273.7 million in 2024, then tumbled by 49.98% to $136.9 million in 2025, then retreated by 27.54% to $99.2 million in 2026.
• Business Quant data shows GOSS's Cash & Current Investments at $99.2 million in Q1 2026, $136.9 million in Q4 2025, and $180.2 million in Q3 2025.